Log in
NYSE:CC

The Chemours Stock Forecast, Price & News

$26.03
+0.34 (+1.32 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$24.90
Now: $26.03
$26.33
50-Day Range
$19.81
MA: $22.72
$25.69
52-Week Range
$7.02
Now: $26.03
$26.33
Volume1.04 million shs
Average Volume2.22 million shs
Market Capitalization$4.28 billion
P/E RatioN/A
Dividend Yield3.89%
Beta2.36
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The Fluoroproducts segment offers fluorochemicals, including refrigerants, foam blowing agents, and propellants under the Freon and Opteon brand names; fluoropolymers, such as industrial resins, specialty products, and coatings under the Teflon, Viton, Krytox, and Nafion brands; and fluoroelastomer products under the Viton brand name for electronics, communications, automotive, wire and cable, energy, oil and gas, aerospace, and other applications. The Chemical Solutions segment provides industrial and specialty chemicals for gold production, consumer, plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining industries. The Titanium Technologies segment manufactures and sells titanium dioxide pigments under the Ti-Pure and BaiMax brands for applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers, and coated papers and paperboards used for packaging. It sell its products through direct channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.
The Chemours logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.89 out of 5 stars


Industry, Sector and Symbol

Industry Chemicals & allied products
Sub-IndustryN/A
CUSIPN/A
Phone302-773-1000
Employees7,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.53 billion
Cash Flow$4.84 per share
Book Value$4.46 per share

Profitability

Net Income$-52,000,000.00

Miscellaneous

Market Cap$4.28 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$26.03
+0.34 (+1.32 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CC News and Ratings via Email

Sign-up to receive the latest news and ratings for CC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











The Chemours (NYSE:CC) Frequently Asked Questions

How has The Chemours' stock been impacted by Coronavirus (COVID-19)?

The Chemours' stock was trading at $10.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CC stock has increased by 144.2% and is now trading at $26.03.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of The Chemours?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Chemours in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for The Chemours
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than The Chemours?

Wall Street analysts have given The Chemours a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but The Chemours wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is The Chemours' next earnings date?

The Chemours is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for The Chemours
.

How were The Chemours' earnings last quarter?

The Chemours Company (NYSE:CC) posted its quarterly earnings results on Sunday, November, 8th. The specialty chemicals company reported $0.47 EPS for the quarter, topping the Zacks' consensus estimate of $0.33 by $0.14. The specialty chemicals company earned $1.23 billion during the quarter, compared to analysts' expectations of $1.20 billion. The Chemours had a positive return on equity of 46.27% and a negative net margin of 2.35%. The company's revenue for the quarter was down 11.3% on a year-over-year basis. During the same period last year, the firm earned $0.59 EPS.
View The Chemours' earnings history
.

How often does The Chemours pay dividends? What is the dividend yield for The Chemours?

The Chemours declared a quarterly dividend on Wednesday, October 28th. Stockholders of record on Monday, November 16th will be given a dividend of $0.25 per share on Wednesday, December 16th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date of this dividend is Friday, November 13th.
View The Chemours' dividend history
.

What price target have analysts set for CC?

11 Wall Street analysts have issued twelve-month price objectives for The Chemours' stock. Their forecasts range from $11.00 to $31.00. On average, they expect The Chemours' stock price to reach $20.09 in the next twelve months. This suggests that the stock has a possible downside of 22.8%.
View analysts' price targets for The Chemours
.

Who are some of The Chemours' key competitors?

What other stocks do shareholders of The Chemours own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

Who are The Chemours' key executives?

The Chemours' management team includes the following people:
  • Mr. Mark P. Vergnano, Pres, CEO & Director (Age 62, Pay $1.18M)
  • Mr. Sameer Ralhan, Sr. VP & CFO (Age 46, Pay $505.44k)
  • Mr. Mark E. Newman, Sr. VP & COO (Age 57, Pay $734.64k)
  • Mr. David C. Shelton Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $577.65k)
  • Mr. E. Bryan Snell, Pres of Titanium Technologies (Age 63, Pay $702.63k)
  • Mr. Edwin C. Sparks, Pres of Chemical Solutions & Fluoroproducts (Age 46, Pay $694.98k)
  • Mr. Matthew S. Abbott, VP, Chief Accounting Officer & Controller (Age 44)
  • Mr. Jonathan Lock, VP of Corp. Devel. & Investor Relations
  • Ms. Alvenia Scarborough, Sr. VP of Corp. Communications & Chief Brand Officer
  • Ms. Susan M. Kelliher, Sr. VP of People & Health Services (Age 53)

What is The Chemours' stock symbol?

The Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Who are The Chemours' major shareholders?

The Chemours' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.15%), LSV Asset Management (2.46%), State Street Corp (2.36%), Allianz Asset Management GmbH (2.21%), Miller Value Partners LLC (2.15%) and Greenlight Capital Inc. (1.85%). Company insiders that own The Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher.
View institutional ownership trends for The Chemours
.

Which major investors are selling The Chemours stock?

CC stock was sold by a variety of institutional investors in the last quarter, including Miller Value Partners LLC, BlackRock Inc., Greenlight Capital Inc., DC Investments Management LLC, DNB Asset Management AS, Voss Capital LLC, First Trust Advisors LP, and Paloma Partners Management Co. Company insiders that have sold The Chemours company stock in the last year include Edwin C Sparks, and Mark P Vergnano.
View insider buying and selling activity for The Chemours
.

Which major investors are buying The Chemours stock?

CC stock was purchased by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Great Lakes Advisors LLC, AQR Capital Management LLC, AJO LP, CHURCHILL MANAGEMENT Corp, Great West Life Assurance Co. Can, Arrowstreet Capital Limited Partnership, and Wells Fargo & Company MN. Company insiders that have bought The Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher.
View insider buying and selling activity for The Chemours
.

How do I buy shares of The Chemours?

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is The Chemours' stock price today?

One share of CC stock can currently be purchased for approximately $26.03.

How big of a company is The Chemours?

The Chemours has a market capitalization of $4.28 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. The Chemours employs 7,000 workers across the globe.

What is The Chemours' official website?

The official website for The Chemours is www.chemours.com.

How can I contact The Chemours?

The Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.